A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder

BACKGROUND AND OBJECTIVE: RP5063 is a novel multimodal dopamine (D)–serotonin (5-HT) stabilizer possessing partial agonist activity for D(2/3/4) and 5-HT(1A/2A), antagonist activity for 5-HT(2B/2C/7,) and moderate affinity for the serotonin transporter. Phase 2 trial data analysis of RP5063 involvin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantillon, Marc, Ings, Robert, Prakash, Arul, Bhat, Laxminarayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133081/
https://www.ncbi.nlm.nih.gov/pubmed/29619682
http://dx.doi.org/10.1007/s13318-018-0472-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133081/
https://www.ncbi.nlm.nih.gov/pubmed/29619682
http://dx.doi.org/10.1007/s13318-018-0472-z

Ejemplares similares